1. Plasma exchange for COVID‐19 thrombo‐inflammatory disease
- Author
-
Nishkantha Arulkumaran, Mari Thomas, David Brealey, Ferras Alwan, Deepak Singh, Michael Lunn, Anna Welch, Samuel Clark, Eamon Raith, Ugan Reddy, Ryan Low, David Leverett, Mervyn Singer, and Marie Scully
- Subjects
COVID‐19 ,inflammation ,lymphopenia ,plasma exchange ,thrombosis ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Severe COVID‐19 disease is a hyperinflammatory, pro‐thrombotic state. We undertook plasma exchange (PEX) to determine its effects on organ function and thrombo‐inflammatory markers. Seven critically ill adults with severe COVID‐19 respiratory failure (PaO2:FiO2 ratio 800 IU/L and D‐dimer >1000 μg/L (or doubling from baseline) received PEX, daily, for a minimum of 5 days. No other immunomodulatory medications were initiated during this period. Seven patients matched for age and baseline biochemistry were a comparator group. Coagulation screening revealed no evidence of coagulopathy. However, von Willebrand Factor (VWF) activity, antigen and VWF antigen: ADAMTS13 ratio, Factor VIII and D‐dimers were all elevated. Following 5 days of PEX, plasma levels of all the above, and ferritin levels, were significantly reduced (P
- Published
- 2021
- Full Text
- View/download PDF